Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen Corp

Repligen provides technology breakthroughs and scalable solutions for the development and manufacture of biologic drugs including plasmid DNA, viral vectors, and mRNA, self-described as a trusted partner in bioprocessing.

COM:REPLIGEN

Repligen

Last Close

141.76

22/11 21:00

Market Cap

7.99B

Beta: -

Volume Today

556.88K

Avg: -

Financials Not Available